

*CytoDyn Securities Litigation Settlement*  
c/o Strategic Claims Services  
600 N. Jackson Street, Suite 205  
Media, PA 19063

***COURT-ORDERED LEGAL NOTICE***

*Brian Joe Courter, et al. v. CytoDyn Inc., et al.*  
Case No. 3:21-cv-05190-BHS (W.D. Wash.)

**Your legal rights may be affected by this securities class action. You may be eligible for a distribution from the Settlement. Please read this Postcard Notice carefully.**

*For more information, please visit*  
**[www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com)**,  
*call toll free 1-866-274-4004,*  
*or send an email to [info@strategicclaims.net](mailto:info@strategicclaims.net)*



***THIS POSTCARD NOTICE PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.  
PLEASE VISIT [WWW.CYTODYNSECURITIESSETTLEMENT.COM](http://WWW.CYTODYNSECURITIESSETTLEMENT.COM) FOR MORE INFORMATION.***

The parties in the securities class action *Brian Joe Courter, et al. v. CytoDyn Inc., et al.*, Case No. 3:21-cv-05190-BHS (W.D. Wash.) (“Action”) have reached a proposed settlement (“Settlement”) of claims asserted in the Action pursuant to Sections 10(b), 20(a) and 20A of the Securities Exchange Act of 1934 (“Exchange Act”) against CytoDyn Inc. (“CytoDyn”), Nader Z. Pourhassan, Michael Mulholland, and Scott A. Kelly (collectively, “Defendants”). If approved, the Settlement will resolve the Action in which the Court-appointed Lead Plaintiff alleged that Defendants’ public disclosures during the relevant time period misrepresented or omitted material facts regarding CytoDyn’s drug leronlimab and its prospects for approval by the U.S. Food and Drug Administration for various applications. Lead Plaintiff further alleged that the price of CytoDyn common stock was artificially inflated as a result of Defendants’ allegedly false and misleading statements, and declined when the alleged corrective disclosures were made. Defendants deny any liability or wrongdoing. You received this notice because you, or an investment account for which you serve as a custodian, may be a member of the following Settlement Class: All persons and entities that purchased or otherwise acquired the common stock of CytoDyn between March 27, 2020 and March 30, 2022, and were damaged thereby.

Pursuant to the Settlement, CytoDyn, on behalf of all Defendants, has agreed to provide to the Settlement Class total consideration of: (i) 49 million shares of CytoDyn common stock and (ii) \$500,000 in cash, which, after deducting Court-awarded fees and expenses, notice and administration costs, and taxes, will be allocated among Settlement Class Members who submit valid claims, in exchange for the Settlement and the release of all claims asserted in the Action and related claims. **For additional information, please review the full Notice (“Notice”) available at [www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com).** If you are a Settlement Class Member, your *pro rata* share of the Settlement will depend on the number of valid claims submitted, and the number, size, and timing of your transactions in CytoDyn common stock during the Class Period. If all Settlement Class Members elect to participate in the Settlement, the estimated average recovery will be approximately \$0.04 per eligible share of CytoDyn common stock (based on the closing price of the stock on March 16, 2026) *before* deducting any fees and expenses. Your actual share of the Settlement will be determined pursuant to the proposed Plan of Allocation set forth in the Notice, or other plan ordered by the Court.

**To qualify for a distribution from the Settlement, you must submit a valid Claim.** The Claim Form can be found and submitted on the website, or you can request that one be mailed to you. **Claims must be postmarked (if mailed), or submitted online, by September 21, 2026.** If you do not want to be legally bound by any releases, judgments, or orders in the Action, **you must exclude yourself** from the Settlement Class by **October 12, 2026.** If you exclude yourself from the Settlement Class, you may be able to sue Defendants about the claims being resolved in the Action, but you cannot get a recovery from the Settlement. If you want to object to any aspect of the Settlement, you must file and serve an objection by **October 12, 2026.** The Notice provides instructions on how to submit a Claim, exclude yourself, or object, and you must comply with all of the instructions in the Notice.

The Court will hold a hearing on **November 2, 2026 at 1:30 p.m.**, to consider, among other things, whether to approve the Settlement and a request by the lawyers representing the Settlement Class for up to 25% of the Settlement Fund in attorneys’ fees, plus litigation expenses of no more than \$300,000 (which equals a cost of approximately \$0.01 per eligible share of CytoDyn common stock). You may attend the hearing and ask to be heard by the Court, but you do not have to. **For more information, call 1-866-274-4004, send an email to [info@strategicclaims.net](mailto:info@strategicclaims.net) or visit [www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com).**